Podcast appearances and mentions of charles vega

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health's three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 2 of the activity, including the value of MCED testing for cancer survivors and ongoing trials investigating MCEDs that he's looking forward to seeing results of in the near future. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. Click here to claim your CME credit: https://bit.ly/41rS14I

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health's three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 3 of the activity, including questions he commonly gets from patients about MCED testing and advice for clinicians about employing shared decision making with patients to choose the most appropriate type of cancer screening for them. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. Click here to claim your CME credit: https://bit.ly/4b9JU00

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health's three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 1 of the activity, including how MCED testing is helping to address the cancer screening gap in the US and the importance of staying up to date on developments in MCED testing. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. Click here to claim your CME credit: https://bit.ly/3X8apxa

In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objective: After completing this educational activity, you should be better able to: Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 45 minutes Released: September 04, 2024*   Expiration: September 03, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credits™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Charles P. Vega, MD Clinical Professor, School of Medicine, University of California - Irvine, Orange, CA Consultant/Advisor: Boehringer Ingelheim, Exact Sciences The remaining Planning Committee member(s), Content Editor(s), Peer Reviewer(s), and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, Samantha Joy, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Claim free CME credit at https://i3health.com/course-information/mced-1 Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. Listen to Module 1 and join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge realm of multicancer early detection (MCED). Dr. Vega will delve into the scientific foundations of blood-based cancer screening, highlighting both current limitations and the promising potential of MCED technologies. Learn how these revolutionary tests harness biomarkers to detect multiple cancers in a single, convenient screening—a game-changer in overcoming barriers like low awareness and limited access to screening facilities.

Claim free CME credit at https://i3health.com/course-information/MCED-2 Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. Join Dr. Charles Vega in Module 2 of our CME podcast as he delves into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, the role of early detection has never been more critical. Dr. Vega will unpack the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, exploring their potential to revolutionize cancer screening and improve patient outcomes.

Claim free CME credit at: https://i3health.com/course-information/mced-3 Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In Module 3 of our CME podcast, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, will explore the practical implementation of multicancer early detection (MCED) tests into clinical practice, offering valuable insights into how these innovations could transform cancer screening and improve patient outcomes.

In this special series on obesity, our host, Dr. Neil Skolnik, discusses the obesity epidemic with some of the foremost experts in the world. In Part 3 of the series, Dr. Skolnik is joined by Drs. Susan Fidler, Charles Vega, and Margot Savoy. Together, they talking about discussing obesity with patients – how to open the conversation on this sensitive topic, how to handle resistance to addressing the topic, and how to avoid stigma and bias. The Focus on Obesity series is a collaborative project of the American Diabetes Association and the American Academy of Family Physicians. The entire program will comprise a total of seven episodes: four episodes of Diabetes Core Update, which will cover topics of interest for family physicians, primary care clinicians, and other health care professionals; as well as three episodes of its sister podcast, Diabetes Day by Day, which will be tailored for people with overweight or obesity and their caregivers. The combined seven-episode program will be released between February and June 2024 and can be freely accessed at https://diabetesjournals.org/journals/pages/podcasts_obesity. Funding support for the “Focus on Obesity” series is jointly provided by Lilly and Novo Nordisk. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Susan Fidler is Associate Director of the Family Medicine Residency Program at Abington Jefferson Health. Charles Vega, M.D., Clinical Professor of Family Medicine, Director, UC Irvine Program in Medical Education for the Latino Community, and Associate Dean in the School of Medicine at the University of California, Irvine. Margot L. Savoy, MD, MPH, FAAFP serves as senior vice president for education, inclusiveness, and physician well-being at the American Academy of Family Physicians

Credits: 0.25 AMA PRA Category 1 Credit™    CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/exploring-strategies-diabetes-obesity-management  Overview: Join primary care physician Charles Vega, MD and renowned endocrinologist Mike Natter, MD, as they explore the profound connection between art, personal health journeys, and medical practice. In this captivating podcast, Dr. Mike Natter will share how his experience as a patient with type 1 diabetes and passion for art have transformed his approach to patient care. Learn about his insights into endocrinology, addressing common misconceptions, and his strategies for caring for patients with diabetes and obesity.

Credits: 0.50 AMA PRA Category 1 Credit™    CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/podcast/pain-management-beyond-pills-surgeries  Overview: Join Dr. Charles Vega as he interviews Dr. Kunal Sood, a leading expert in interventional pain medicine who specializes in diagnosing and treating chronic neck, back, and joint pain. Learn from his wealth of experience as he demystifies misconceptions about pain management, shares insights into the world of pain management, and discusses the role pain specialists in care of patients with chronic pain. 

In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Residual Risk, Triglycerides and how to reduce residual risk with Dr. Charles Vega, Clinical Professor of Family Medicine and Associate Dean in the School of Medicine at the University of California, Irvine. This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Charles Vega, M.D., Clinical Professor of Family Medicine, Director, UC Irvine Program in Medical Education for the Latino Community, and Associate Dean in the School of Medicine at the University of California, Irvine.   Selected references referred to the in the Podcast: Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22 ADA Standards of Care: Diabetes Care 2023;46(Supplement_1):S158–S190 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168 See Episode 1 for further references.

CME credits: 0.25 Valid until: 16-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/patient-centered-communications-and-shared-decision-making-in-the-management-of-obesity/15361/ Obesity and overweight have reached epidemic status in the US. While safe and effective treatment options are available, it remains a challenge for clinicians to initiate conversations about weight with their patients. Learn how to open channels of communication with your patients by watching Dr. Charles Vega interact with a 42-year-old patient using shared decision-making.=

CME credits: 0.25 Valid until: 06-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-barriers-for-vulnerable-patients-with-diabetic-eye-disease/15347/ New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who are less likely to access routine healthcare. Tune in to hear Dr. Sharon Solomon and Dr. Charles Vega discuss how the latest clinical data measure up by prolonging treatment intervals and how retina specialists are now better equipped to care for their most vulnerable patients with DME.=

CME credits: 0.25 Valid until: 06-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/strategies-to-reduce-treatment-burden-for-vulnerable-patients-with-diabetic-eye-disease/15355/ Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.=

CME credits: 0.25 Valid until: 26-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-you-need-to-know-about-weight-loss-medications/15360/ Obesity is a chronic, progressive disease which has often been overlooked by physicians, leaving a considerable proportion of people with obesity underdiagnosed and inappropriately managed. Join Drs. Charles Vega and Donna Ryan as they break down the pathophysiology of obesity and discuss currently available weight-loss medications.=

CME credits: 0.25 Valid until: 26-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-challenge-in-obesity-medical-management/15359/ Addressing the health issues of your patients with obesity can present a challenge. How can you initiate the conversation and effectively emphasize the benefits of weight loss? Join Drs. Charles Vega and Donna Ryan as they review a case of obesity and use evidence-based medicine to develop a patient-centric treatment plan.=

CME credits: 0.25 Valid until: 26-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/examining-disparities-in-diabetic-eye-health/15346/ Racial and ethnic minorities are disproportionately affected by diabetic eye disease, which is one of the leading causes of vision loss in the United States. Hear how Dr. Ruth Shoge and Dr. Charles Vega are approaching patient care and find out what tools are available to you. Join us in overcoming barriers to vision care so that all patients can receive the treatment they need.=

Charles Vega P.A. is a Florida-based lawyer who arrived into the legal profession later in life. After a successful corporate career, Charles made the decision to fulfil his life long dream of becoming an Attorney. Having completed Law School part time at night, he opened a now hugely successful Legal Practice and today, Charles speaks to David Lock KC about the challenges he faced perusing that dream and the lessons he has learnt along the way. Enjoy! - Breaking Legal Glass Ceilings is a series of conversations with leading lawyers from backgrounds outside the law. David Lock KC explores how successful lawyers made it into the professions, what they did to get on, what legal practice demanded from them, what they did to stand out from their peers, and their top tips for the aspiring lawyers of tomorrow. We would also like to invite you to join the conversation, and you can email us with your comments and questions at legalglassceilings@gmail.com, and you can find us on Twitter, Instagram, and LinkedIn. We look forward to sharing these conversations with you, and very much hope you enjoy them. Hosted by David Lock KC Produced & Edited by Amy Jansen

CME credits: 0.25 Valid until: 13-10-2023 Claim your CME credit at https://reachmd.com/programs/cme/covid-19-updates-on-best-practices-to-improve-outcomes/14091/ Newer therapeutic options are now available to treat COVID-19. Don't panic! Drs. Charles Vega and Paul Auwaerter are here to help you successfully integrate these therapeutics into your practice. Find out how to identify patients that are at risk for severe disease and select the appropriate treatment for the patient in front of you.

CME credits: 0.25 Valid until: 13-10-2023 Claim your CME credit at https://reachmd.com/programs/cme/covid-19-differentiating-disease-course-and-updates-on-treatment/14090/ Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.

Host: Charles P. Vega, MD Guest: Paul G. Auwaerter, MD, MBA Newer therapeutic options are now available to treat COVID-19. Don't panic! Drs. Charles Vega and Paul Auwaerter are here to help you successfully integrate these therapeutics into your practice. Find out how to identify patients that are at risk for severe disease and select the appropriate treatment for the patient in front of you.

Host: Charles P. Vega, MD Guest: David J. Cennimo, MD, FACP, FAAP, FIDSA Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.

Program director Dr. Charles Vega and 2016graduate Dr. Michelle Crespo join the UCI Podcast to talk about the Program in Medical Education for the Latino Community's vast influence on improving healthcare in California and on UC Irvine's status as an Hispanic-Serving Institution.

Stella A. Safo, MD, MPH and Charles Vega, MD discuss how health care providers can improve access to COVID-19 treatment for people from racial/ethnic minority groups. Topics: *Who is receiving treatment for mild to moderate COVID-19? *How the social determinants of health affect COVID-19 risk *Examining COVID-19 outcomes by race and ethnicity *Improving access to treatment Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/3-1-22-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Stella Safo, MD, MPH, Just Equity For Health, Founder and Executive Director, Assistant Professor Mount Sinai Health System Charles Vega, MD, Clinical Professor, Family Medicine, School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine, School of Medicine, Associate Dean, School of Medicine at University of California, Irvine See acast.com/privacy for privacy and opt-out information.

On today's episode, I interviewed Charles Vega. Charles is an attorney in Daytona Beach, Florida. It's a bit strange, but we have almost the exact same story. Both Charles and I were in business for multiple years and law is our 3rd or 4th career. We both went to school late in life, started a solo practice, and even right down to the fact that we are both practicing martial artists as well. I almost feel like I'm interviewing myself! You are going to hear how Charles started his solo firm and has since grown it to be the size he wants it to be as he continues to enjoy the ride and go for as long as he can. I am delighted to present to you Charles Vega.    In this episode, Neil and Charles discuss: Being an older law student and beginning your law career with a robust work history.  Growing a remote law firm. Utilizing past experience to hire the right team members.  Enjoying both life and work.    Key Takeaways: Seasoned veterans bring their own networks to law firms.  Hiring the right talent is important. You are only as strong as the people who work for you.  As a lawyer, it is important to know what you want your exit strategy to be and build that in from the beginning.  Enjoy where you are now and embrace this time of your life.    "Even though I came late in practice, I've known a lot of people and people that know I'm a professional, call me because even though they know I've not been doing it a long time, they'll know that because of my reputation, I'll take care of them and help them resolve their problem." —  Charles Vega   Get in touch with Charles Vega Phone: 1-800-975-0529 Website: https://charlesvegapa.com/ (https://charlesvegapa.com/)      Thank you to our sponsors! http://callruby.com/lawentrepreneur (Ruby Receptionist) - Virtual receptionist & live call services that will help you grow your office (and save money), one call at a time - to learn more, go to http://callruby.com/lawentrepreneur (callruby.com/lawentrepreneur) or call 844.895.7829 Coach Rockwell - Mark Rockwell works with lawyers who are frustrated by their inability to scale up and become more profitable. He helps them create their vision, and implement an operating platform that builds healthy, thriving law firms. Reach out to him at mark@coachrockwell.com or 503.784.7205 Get in touch with Neil: Website: https://thelawentrepreneur.com/ (https://thelawentrepreneur.com/) Twitter: https://twitter.com/lawentrepreneur (https://twitter.com/lawentrepreneur) Facebook: https://www.facebook.com/thelawentrepreneur/?ref=hl (https://www.facebook.com/thelawentrepreneur/?ref=hl) LinkedIn: https://www.linkedin.com/in/tyralawfirm/ (https://www.linkedin.com/in/tyralawfirm/) If you've enjoyed the podcast, http://getpodcast.reviews/id/1086406592 (please head to Apple Podcasts and leave a rating & review for the show)! It only takes a moment, and really helps me to reach new listeners. You can also http://www.thelawentrepreneur.com/ (head to the website at TheLawEntrepreneur.com) for more information on the podcast and my legal services.    Show notes by Podcastologist Chelsea Taylor-Sturkie   Audio production byhttps://www.turnkeypodcast.com/ ( Turnkey Podcast Productions.) You're the expert. Your podcast will prove it. 

Paul G. Auwaerter, MD, MBA, FIDSA and Charles Vega, MD discuss the latest in COVID-19 treatment news including the Omicron variant. Topics: *Effective treatments for COVID-19 caused by Omicron variant *New antiviral, and other new and in-the-pipeline treatments *Assessing impact of COVID-19 on vulnerable populations and inequities by race/ethnicity *Q&A Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/1-25-22-episode/evalAccess our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Paul G. Auwaerter, MD, MBA, FIDSA, Past President of the Infectious Diseases Society of America (IDSA), Professor of Medicine, Johns Hopkins University School of Medicine Charles Vega, MD, Clinical Professor, Family Medicine, School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine, School of Medicine, Associate Dean, School of Medicine at University of California, Irvine See acast.com/privacy for privacy and opt-out information.

Michael Angarone, DO, FIDSA and Charles Vega, MD discuss the latest COVID-19 treatment guidelines and recommendations. Topics:New treatments for COVID-19Assessing impact of COVID-19 on vulnerable populations and disparities by race/ethnicityTreating patients hospitalized with COVID-19Live Q&APost-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/12-7-21-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Michael Angarone, DO, FIDSAAssociate ProfessorDivision of Infectious DiseasesDepartments of Medicine and Medical EducationNorthwestern University Feinberg School of MedicineCharles Vega, MD - Hub Faculty (Family Medicine)Clinical Professor, Family MedicineSchool of MedicineDirector, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family MedicineSchool of MedicineAssociate DeanSchool of MedicineUniversity of California, Irvine See acast.com/privacy for privacy and opt-out information.

Aimalohi Ahonkhai, MD, MPH and Charles Vega, MD discuss what we can do to address COVID-19 inequalities. Topics: *Structural barriers to health care and vaccine access *Tools to reduce inequities *Real COVID-19 patient stories *The latest data on medications to prevent and treat COVID-19, including a potential new oral medication Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/11-2-21-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Aimalohi Ahonkhai, MD, MPH, Assistant Professor of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center Charles Vega, MD, Clinical Professor, Family Medicine, School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine, School of Medicine, Associate Dean, School of Medicine at University of California, Irvine See acast.com/privacy for privacy and opt-out information.

Host: Jennifer Caudle, DO Guest: Charles P. Vega, MD The development of mRNA vaccines marked a turning point in the battle against the COVID-19 pandemic, but what do we need to know about this emerging vaccine technology? Dr. Jennifer Caudle and Dr. Charles Vega, a Clinical Professor in the Department of Family Medicine at the University of California Irvine, discuss some of the benefits and common concerns.

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/influenza-populations-at-high-risk-1 Overview: This brief podcast will answer your most salient questions about managing influenza in high-risk patients, starting with how to identify those patients and determine their risk for developing complications. Next, you will listen to the experts discuss the latest CDC and IDSA recommendations for preventing influenza—including the use of post-exposure prophylaxis—in this vulnerable patient population. Finally, you will hear the recommendations for testing for influenza—within the context of the COVID-19 pandemic—and treating patients with influenza at high risk for complications Hosts: Mary W. Montgomery, MD; Charles Vega, MD, FAAFP Executive Producer: Margaret Oliverio, MD

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit:  Overview: In this short podcast, you will hear guideline-based answers to important questions about managing influenza in the pediatric population. Find out which children are considered high risk for complications and what those risks mean for vaccine selection. Hear expert tips on how to discuss the sensitive issue of influenza vaccination with vaccine-hesitant parents. Know how to accurately diagnose influenza in children in the midst of the COVID-19 pandemic. And lastly, learn which influenza treatments are approved for children and the role antivirals play in influenza prophylaxis in this population. Hosts: Robert H. Hopkins Jr., MD, FACP, FAAP; Charles Vega, MD, FAAFP Executive Producer: Margaret Oliverio, MD

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/influenza-populations-at-high-risk-2 Overview: This expert-led podcast arms you with what you need to know to effectively manage influenza in older adults, a population at increased risk for complications. Get the latest guidance on everything from choosing the appropriate vaccine for this age group to preventing the spread of influenza in long-term care facilities. Hear the most up-to-date recommendations for how to diagnose and treat older adults with influenza and find out if there are any risks associated with antivirals for this patient population. If you provide care to older adults this influenza season, you can't miss this session. Hosts: Mary W. Montgomery, MD; Charles Vega, MD, FAAFP Executive Producer: Margaret Oliverio, MD  

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/influenza-populations-at-high-risk-3 Overview: Join us to discover why it is important to prevent influenza and treat patients with influenza who have cardiometabolic disease. After this brief podcast, you will be able to identify the types of cardiovascular and metabolic diseases that put patients at high risk of influenza complications and determine which patients should get the high-dose influenza vaccine, according to recent data. You will also be able to answer the question of whether anti-influenza drugs affect the risk of incident cardiovascular events. Find out all this and more to protect your patients with cardiometabolic disease this influenza season. Hosts: Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC; Charles Vega, MD, FAAFP Executive Producer: Margaret Oliverio, MD

Aimalohi Ahonkhai, MD, MPH and Charles Vega, MD discuss what we can do to address COVID-19 inequalities. Topics: *Vaccination inequalities *How social determinants of health determine COVID-19 risk *How variants are impacting treatment decisions *Real COVID-19 patient stories Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/10-1-21-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Aimalohi Ahonkhai, MD, MPH, Assistant Professor of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center Charles Vega, MD, Clinical Professor, Family Medicine, School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine, School of Medicine, Associate Dean, School of Medicine at University of California, Irvine See acast.com/privacy for privacy and opt-out information.

Drs. Charles Vega and Dinora Chinchilla discuss ways we can address the COVID-19 health outcome disparities. Topics: *Real COVID-19 patient stories *COVID-19 health outcomes based on ethnicity and socioeconomic status *How social determinants of health determine COVID-19 risk *How to better treat minority patients Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/8-24-21-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Charles Vega, MD, Clinical Professor, Family Medicine, School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine, School of Medicine, Associate Dean, School of Medicine at University of California, Irvine Dinora Chinchilla, MD, Health Sciences Assistant Clinical Professor, UC Irvine Department of Pulmonary Critical Care, UC Irvine School of Medicine See acast.com/privacy for privacy and opt-out information.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/BNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an influenza expert discusses the latest clinical evidence and current guideline recommendations on the use of antiviral therapy in the treatment of influenza. Upon completion of this accredited CE activity, participants should be better able to: Summarize guideline recommendations regarding the use of antiviral therapy in the treatment of influenza, especially for patients at high risk of complications, Compare currently available and novel/emerging antiviral therapies for the treatment of influenza with regard to mechanisms of action, efficacy, safety, tolerability, and dosing, Select antiviral treatment for both adult and pediatric patients with influenza based on the latest clinical evidence and current guideline recommendations.

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/act-fast-case-study-postexposure-influenza-prophylaxis/12734/ Post-exposure influenza prophylaxis should be a top-of-mind discussion with patients receiving an influenza diagnosis. Unfortunately, it remains an underused means to reduce secondary infections in at-risk households. Join Drs. Cassandra Donnelly and Charles Vega as they examine an extended patient case and offer practical strategies to overcome common clinical barriers surrounding post-exposure influenza prophylaxis, including how to match the right patient with the right antiviral treatment.

CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/act-fast-case-study-postexposure-influenza-prophylaxis/12734/ Post-exposure influenza prophylaxis should be a top-of-mind discussion with patients receiving an influenza diagnosis. Unfortunately, it remains an underused means to reduce secondary infections in at-risk households. Join Drs. Cassandra Donnelly and Charles Vega as they examine an extended patient case and offer practical strategies to overcome common clinical barriers surrounding post-exposure influenza prophylaxis, including how to match the right patient with the right antiviral treatment.

CME credits: 0.25 Valid until: 13-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/act-fast-understanding-flu-prevention-and-treatment-risk-populations/12717/ Antiviral agents are underutilized against influenza in clinical practice, a failure that places many patients, especially those with comorbidities, at high risk for influenza-associated complications. Join Drs. Cassandra Donnelly and Charles Vega as they explore management strategies for patients with symptomatic influenza, compare and contrast clinical applications for the available antiviral agents, and reflect upon the increasing use of these agents as post-exposure influenza prophylaxis.

CME credits: 0.25 Valid until: 13-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/act-fast-understanding-flu-prevention-and-treatment-risk-populations/12717/ Antiviral agents are underutilized against influenza in clinical practice, a failure that places many patients, especially those with comorbidities, at high risk for influenza-associated complications. Join Drs. Cassandra Donnelly and Charles Vega as they explore management strategies for patients with symptomatic influenza, compare and contrast clinical applications for the available antiviral agents, and reflect upon the increasing use of these agents as post-exposure influenza prophylaxis.

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/stop-hiv-together-2 Overview: The Ending the HIV Epidemic (EHE) initiative aims to reduce new HIV infections in the U.S. by 90% by 2030. This aim will be achieved by equitably and collaboratively delivering care and focusing resources on communities most affected by HIV, including those in Southern and rural areas. Join Dr. Charles Vega, Health Sciences Clinical Professor at UC Irvine Department of Family Medicine, and Dr. Leandro Mena, Chair and Professor of the Department of Population Health Science at University of Mississippi, and Director of the Center for HIV/AIDS Research, as they discuss how to provide culturally competent and collaborative care using the four EHE strategies: diagnose, treat, prevent, and respond. Guest: Leandro Mena, MD, MPH

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/stop-hiv-together-1 Overview: HIV remains a persistent health problem for the United States and countries around the world. June marks 40 years since the first report of AIDS in CDC's MMWR. Great progress has happened in the last 40 years in preventing and treating HIV. Yet there is still much to do. Join Dr. Charles Vega, Health Sciences Clinical Professor at UC Irvine Department of Family Medicine, and Dr. Oni Blackstock, primary care and HIV physician, researcher, and founder and executive director of Health Justice, racial and health equity consulting practice as they discuss how health and social inequities continue to affect the HIV epidemic. They will talk about the role primary care providers can play in ending the HIV epidemic. Guest: Oni Blackstock, MD, MHS

Credits: 0.50 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/stop-hiv-together-1 Overview: HIV remains a persistent health problem for the United States and countries around the world. June marks 40 years since the first report of AIDS in CDC's MMWR. Great progress has happened in the last 40 years in preventing and treating HIV. Yet there is still much to do. Join Dr. Charles Vega, Health Sciences Clinical Professor at UC Irvine Department of Family Medicine, and Dr. Oni Blackstock, primary care and HIV physician, researcher, and founder and executive director of Health Justice, racial and health equity consulting practice as they discuss how health and social inequities continue to affect the HIV epidemic. They will talk about the role primary care providers can play in ending the HIV epidemic. Guest: Oni Blackstock, MD, MHS

Credits: 0.50 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/stop-hiv-together-2 Overview: The Ending the HIV Epidemic (EHE) initiative aims to reduce new HIV infections in the U.S. by 90% by 2030. This aim will be achieved by equitably and collaboratively delivering care and focusing resources on communities most affected by HIV, including those in Southern and rural areas. Join Dr. Charles Vega, Health Sciences Clinical Professor at UC Irvine Department of Family Medicine, and Dr. Leandro Mena, Chair and Professor of the Department of Population Health Science at University of Mississippi, and Director of the Center for HIV/AIDS Research, as they discuss how to provide culturally competent and collaborative care using the four EHE strategies: diagnose, treat, prevent, and respond. Guest: Leandro Mena, MD, MPH

Drs. Charles Vega and Aima A. Ahonkha discuss ways we can address the COVID-19 health outcome disparities. Topics: Real COVID-19 patient stories COVID-19 health outcomes based on ethnicity and socioeconomic status How social determinants of health determine COVID-19 risk Treating hospitalized and ambulatory patients Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/6-18-21-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Charles Vega, MD, FAAFP Health Sciences Clinical Professor UC Irvine Department of Family Medicine Assistant Dean for Culture and Community Education UC Irvine School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community Irvine, CA Aima A. Ahonkhai, MD, MPH Assistant Professor of Medicine Division of Infectious Diseases Vanderbilt University Medical Center See acast.com/privacy for privacy and opt-out information.

In this live webinar, Charles Vega, MD and Michael Angarone, DO, FIDSA analyze two COVID-19 patient case studies: one patient is experiencing moderate symptoms and the other is in the hospital with severe symptoms. Can you make the right treatment decisions? They discuss: Accurately identifying patients eligible for authorized treatments Viral variants' impact on treatments The latest treatment recommendations and clinical data Expert Faculty Charles Vega, MD Clinical Professor, Family Medicine Director, UC Irvine Program in Medical Education for the Latino Community, Family Medicine School of Medicine Assistant Dean for Culture and Community Education UC Irvine School of Medicine Michael Angarone, DO, FIDSA Associate Professor Division of Infectious Diseases Departments of Medicine and Medical Education Northwestern University Feinberg School of Medicine See acast.com/privacy for privacy and opt-out information.

Drs. Paul Auwaerter and Charles Vega discuss the various COVID-19 treatment options and answer your questions. Topics: *Analyzing how strain variants impact COVID-19 treatment *Understanding treatment options for ambulatory and hospitalized patients *Accurately identifying patients eligible for monoclonal antibodies *Understanding when, how, and why various treatments work Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/4-28-21-session/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Paul G. Auwaerter, MD, MBA, FIDSAPast President of the Infectious Diseases Society of America (IDSA) and Professor of Medicine at Johns Hopkins University School of Medicine Charles Vega, MD, FAAFPHealth Sciences Clinical Professor at UC Irvine Department of Family MedicineAssistant Dean for Culture and Community Education at UC Irvine School of MedicineDirector, UC Irvine Program in Medical Education for the Latino Community See acast.com/privacy for privacy and opt-out information.

056: The Jeff & Heidi Show with Charles Vega Jeff Heggie www.JeffHeggie.com mindset.JeffHeggie.com Heidi Anderson www.ECISecurePay.com Charles Vega The Law Firm of Charles Vega P.A. located in Daytona Beach, Florida. Serving Central, South and North Florida, (practice is limited to the State of Florida). Charles Vega is an attorney at Law and a Public Speaker. Charles Vega is a very determined individual who after working for fortune 500 companies decided to change careers later in life, so he worked full time during the day, studied to be accepted at a law school, was accepted and attended law school part-time at night, commuting 180 miles a day, four nights a week, for 3 ½ years. He put over 120,000 miles on his car, studied every weekend and used all his vacation time to study. Passed the bar the first time, became an attorney and finally reached his dream of leading his own law firm. He contributes his success to setting goals, stay focused and to keep driving forward until you reach that goal! Don't let anyone tell you it can't be done. Be honest with people, treat people like you would want to be treated, and build long term trusting relationships. Charles is available for motivational speaking events, and offers free 30 minute legal consultations. You can learn more about the Law Firm of Charles Vega P.A. at www.charlesvegapa.com. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

In this week's episode, Drew and Corbin talk with Florida Attorney, Charles Vega, and discuss everything from navigating the intricacies of law school to what it is like being a practicing attorney after that law school storm passes. It was a pleasure to have Charles on the show and we hope you guys enjoy listening to him as much as we did. Charles has his own law firm that practices in several areas of law including Real Estate, Commercial Law, Personal Injury, and Estate Planning. You can find out more about Charles and his work at www.charlesvegapa.com.

In this episode, Charles Vega, MD, Professor of Family Medicine at UC Irvine, will address the clinical impact of herpes zoster, the efficacy, tolerability, and safety of available vaccines for prevention, and strategies to promote adherence to national vaccine guidelines.Herpes zoster, or shingles, results from reactivation of the varicella-zoster virus (VZV) that lies dormant on the dorsal horn nerve cells of the spinal cord. The annual incidence increases with age, from five cases per 1,000 population in adults aged 50-59 years to 11 cases per 1,000 population in persons aged ≥80 years. Approximately 99.5% of people aged ≥40 years born in the United States have been infected with wild-type VZV and are therefore at risk for herpes zoster. Vaccination can reduce the risk of herpes zoster and postherpetic neuralgia (PHN), and a newer vaccine with greater effectiveness is now available. However, various barriers to vaccination exist, and vaccination coverage is suboptimal.This educational activity is supported by an educational grant from GlaxoSmithKline.This activity is not certified for CME/CE credit.